Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 25:9:51.
doi: 10.1186/s13578-019-0316-9. eCollection 2019.

Regulation of platelet-activating factor-mediated interleukin-6 promoter activation by the 48 kDa but not the 45 kDa isoform of protein tyrosine phosphatase non-receptor type 2

Affiliations

Regulation of platelet-activating factor-mediated interleukin-6 promoter activation by the 48 kDa but not the 45 kDa isoform of protein tyrosine phosphatase non-receptor type 2

Geneviève Hamel-Côté et al. Cell Biosci. .

Abstract

Background: An underlying state of inflammation is thought to be an important cause of cardiovascular disease. Among cells involved in the early steps of atherosclerosis, monocyte-derived dendritic cells (Mo-DCs) respond to inflammatory stimuli, including platelet-activating factor (PAF), by the induction of various cytokines, such as interleukin 6 (IL-6). PAF is a potent phospholipid mediator involved in both the onset and progression of atherosclerosis. It mediates its effects by binding to its cognate G-protein coupled receptor, PAFR. Activation of PAFR-induced signaling pathways is tightly coordinated to ensure specific cell responses.

Results: Here, we report that PAF stimulated the phosphatase activity of both the 45 and 48 kDa isoforms of the protein tyrosine phosphatase non-receptor type 2 (PTPN2). However, we found that only the 48 kDa PTPN2 isoform has a role in PAFR-induced signal transduction, leading to activation of the IL-6 promoter. In luciferase reporter assays, expression of the 48 kDa, but not the 45 kDa, PTPN2 isoform increased human IL-6 (hIL-6) promoter activity by 40% after PAF stimulation of HEK-293 cells, stably transfected with PAFR (HEK-PAFR). Our results suggest that the differential localization of the PTPN2 isoforms and the differences in PAF-induced phosphatase activation may contribute to the divergent modulation of PAF-induced IL-6 promoter activation. The involvement of PTPN2 in PAF-induced IL-6 expression was confirmed in immature Mo-DCs (iMo-DCs), using siRNAs targeting the two isoforms of PTPN2, where siRNAs against the 48 kDa PTPN2 significantly inhibited PAF-stimulated IL-6 mRNA expression. Pharmacological inhibition of several signaling pathways suggested a role for PTPN2 in early signaling events. Results obtained by Western blot confirmed that PTPN2 increased the activation of the PI3K/Akt pathway via the modulation of protein kinase D (PKD) activity. WT PKD expression counteracted the effect of PTPN2 on PAF-induced IL-6 promoter transactivation and phosphorylation of Akt. Using siRNAs targeting the individual isoforms of PTPN2, we confirmed that these pathways were also active in iMo-DCs.

Conclusion: Taken together, our data suggest that PTPN2, in an isoform-specific manner, could be involved in the positive regulation of PI3K/Akt activation, via the modulation of PKD activity, allowing for the maximal induction of PAF-stimulated IL-6 mRNA expression.

Keywords: GPCR; IL-6; PTPN2; Platelet-activating factor; Protein tyrosine phosphatase; TC-PTP.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Differential effects of PTPN2 isoforms on PAF-induced IL-6 expression. a HEK-PAFR were transiently co-transfected with the hIL-6-luc, control vector (pcDNA3) or phosphatase constructs a WT and b D182A mutants. Cells were incubated overnight in DMEM-0.2% BSA and stimulated with a, b PAF (100 nM), vehicle or a TNF-α (20 ng/ml) for 6 h and luciferase activity was measured. The data presented are a mean ± SEM of 6–16 independent experiments performed in triplicate. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05. c iMo-DCs were either not transfected (NT) or transfected with siRNAs: either control (siCTRL) or against isoforms of PTPN2 (siPTPN2 48 kDa or 45 kDa) on day 4 and 5 before being collected on day 7 for experiments. iMo-DCs were starved for 3 h in RPMI 0.2% BSA and stimulated with PAF (1 nM) for 5 h. Cells were lysed in Trizol and RNA was extracted and converted to cDNA. IL-6 mRNA was quantified by real-time PCR. Data are presented as mean ± SEM of mRNA expression calculated by the delta–delta (ΔΔ)Ct method on their respective unstimulated control for 4 independent experiments, using RPL13A and GAPDH as housekeeping genes. Significance was established with two-way ANOVA with Sidak post-test, *p < 0.05
Fig. 2
Fig. 2
PAF modulates 45 kDa and 48 kDa PTPN2 activity but not the 45 kDa PTPN2 localization. a Graph represents the phosphatase activity determined by the hydrolysis rate of pNPP by Flag-tagged PTPN2, immunoprecipitated from HEK-PAFR which had been starved overnight in DMEM 0.2% BSA before being stimulated with 100 nM PAF, for indicated times. After PTP experiments, proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted overnight with anti-PTPN2 antibodies for normalization of pNPP rates. Data are presented as low–high graphs (with lines at mean) of normalized pNPP hydrolysis rates for 3 independent experiments. Significance was established with paired two-way ANOVA with Sidak post-test. *p < 0.05. b, c HEK-PAFR, grown on poly-l-lysine coated coverslips, were transfected with Venus-tagged D182A-PTPN2 then stimulated, 30 h later, with vehicle or 100 nM PAF for 2, 5 or 10 min before permeabilization with 0.5% Triton X-100. Nuclei were stained with DAPI and cells were analyzed by confocal microscopy. Results are representative of 4 independent experiments, with at least 28 pictures analyzed from different fields per condition. Scale bar = 5 µm. b Compilation of Pearsons’ and Manders’ Coefficients for PTPN2. Data presented are mean ± SEM of 4 independent experiments and c representative pictures of Venus-tagged D182A 45 kDa or 48 kDa-D182A PTPN2 isoforms
Fig. 3
Fig. 3
Modulation of PAF-induced IL-6 promoter activity by 48 kDa PTPN2 depends on multiple signaling pathways. HEK-PAFR were transiently co-transfected with the hIL-6-luc, control vector (pcDNA3), or the 48 kDa or 45 kDa PTPN2 constructs. Cells were incubated overnight in DMEM-0.2% BSA and ae pre-treated for 30 min in DMEM-0.2%BSA with DMSO as vehicle control or a MEK 1/2 inhibitor U-0126, 5 µM, b JNK inhibitor SP600125, 1 µM, c pan PKC inhibitor GF109203x 2 µM or d Src kinase family inhibitor PP2, 10 nM and e Jak2 inhibitor AG490 5 µM. Stimulation with PAF (100 nM) or vehicle was for 6 h and luciferase activity was then measured. The data presented are a mean ± SEM of at least 4 independent experiments performed in triplicate. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05, **p < 0.01
Fig. 4
Fig. 4
48 kDa PTPN2 modulation of PAF-induced hIL-6 promoter activity does not depend on G-protein activation. HEK-293 were transiently co-transfected with the hIL-6-luc, wild type or mutant PAFRs and control vector (pcDNA3) or the 48 kDa PTPN2 constructs. Cells were incubated overnight in DMEM-0.2% BSA, stimulated with PAF (100 nM) or vehicle for 6 h and luciferase activity was measured. The data presented are mean ± SEM of 4–5 independent experiments performed in triplicate. Significance was established with paired Student’s t test. **p < 0.01
Fig. 5
Fig. 5
48 kDa PTPN2 modulates PAF-induced Akt activation in iMoDCs. Immature monocyte-derived dendritic cells (iMo-DCs) were transfected with control siRNAs (siCTRL) or against isoforms of PTPN2 (siPTPN2 48 kDa or 45 kDa) on day 4 and 5 before being collected on day 7 for experiments. iMo-DCs were starved for 5 h in RPM1 + 0.2% BSA and stimulated with PAF (1 nM) for indicated times. Whole cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted overnight with anti-pSer473Akt, anti-Akt and anti-actin antibodies. a Representative blots and b compilations of at least 4 independent experiments are shown. The data presented are a mean ± SEM. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05, **p < 0.01
Fig. 6
Fig. 6
48 kDa PTPN2 modulates PAF-induced PKD activation in HEK-PAFR. a HEK-PAFR were transiently transfected with 48 kDa or 45 kDa PTPN2 cDNAs or control vector. Cells were incubated overnight in DMEM-0.2% BSA, then stimulated with PAF (100 nM) or vehicle for indicated times. Whole cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted overnight with anti-pSer910 PKD then anti-PKD antibodies, after stripping. a Representative blots and b compilations of 3 independent experiments are shown. The data presented are a mean ± SEM. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05
Fig. 7
Fig. 7
48 kDa PTPN2 modulates PAF-induced PKD activation in iMoDCs. Immature monocyte-derived dendritic cells (iMo-DCs) were transfected with control siRNAs (siCTRL) or siRNAs against isoforms of PTPN2 (siPTPN2 48 kDa or 45 kDa) on day 4 and 5 before being collected on day 7 for experiments; or not transfected (NT). iMo-DCs were starved for 5 h in RPM1 + 0.2% BSA and stimulated with PAF (1 nM) for indicated times. Whole cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted overnight with anti-pSer910 PKD, anti-PKD and anti-actin antibodies. NT samples have been loaded on the same blots as PTPN2 samples, to serve as controls. a Representative blots and b compilations of at least 3 independent experiments are shown. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05, **p < 0.01
Fig. 8
Fig. 8
48 kDa PTPN2 forms a signaling complex with PKD and Akt. HEK-PAFR were transiently transfected with D182A-48 kDa or − 45 kDa PTPN2 constructs tagged with Flag or control vector (Ctrl). Cells were incubated overnight in DMEM-0.2% BSA, then stimulated with PAF (100 nM) or vehicle for indicated times. Stimulation was stopped on ice, cells were scraped and lysed. Whole cell lysates were submitted to immunoprecipitation using anti-FLAG antibodies coupled to agarose beads. a Precipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted overnight with anti-Akt, anti-PKD or anti-Flag antibodies. Lysate samples have been loaded onto the same blots as immunoprecipitated PTPN2 samples and serve as loading controls. a Representative blots and b compilations of at least 3 independent experiments are shown. The data presented are mean ± SEM. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05
Fig. 9
Fig. 9
48 kDa PTPN2 modulates Akt activation via a PKD-dependent pathway. a, b HEK-PAFR were transiently transfected with 48 kDa or 45 kDa PTPN2 constructs tagged with FLAG, PKD tagged with GST or control vectors (pcDNA3 or pcDNA3-GST). Cells were incubated overnight in DMEM-0.2% BSA, then stimulated with PAF (100 nM) or vehicle for indicated times. Stimulation was stopped on ice, cells were scraped and lysed. Whole cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted overnight with anti-pSer473Akt, anti-GST, anti-actin, anti-FLAG and anti-Akt antibodies. Results shown are a compilation of 3 independent experiments, expressed as variations of Akt phosphorylation due to PTPN2 overexpression where values of pAkt levels of control cells (without PTPN2) are set to 1 (Dotted line) for each indicated stimulation time. c HEK-PAFR were transiently co-transfected with the hIL-6-luc, control vector pcDNA3, 48 kDa PTPN2 or PKD constructs. Cells were incubated overnight in DMEM-0.2% BSA and stimulated with PAF (100 nM) or vehicle for 6 h and luciferase activity was measured. The data presented are mean ± SEM of at least 3 experiments performed in triplicate. ac The data presented are mean ± SEM. Significance was established with two-way ANOVA with Sidak post-test. *p < 0.05
Fig. 10
Fig. 10
Schematic representation of pathways involved in PAF-induced PTPN2 modulation of IL-6 expression

Similar articles

Cited by

References

    1. Naugler WE, Karin M. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109–119. doi: 10.1016/j.molmed.2007.12.007. - DOI - PubMed
    1. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165–197. doi: 10.1146/annurev.immunol.021908.132620. - DOI - PMC - PubMed
    1. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor—a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105(11):705–716. doi: 10.1002/ejlt.200300845. - DOI
    1. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669–1699. doi: 10.1152/physrev.2000.80.4.1669. - DOI - PubMed
    1. Brown SL, Jala VR, Raghuwanshi SK, Nasser MW, Haribabu B, Richardson RM. Activation and regulation of platelet-activating factor receptor: role of G(i) and G(q) in receptor-mediated chemotactic, cytotoxic, and cross-regulatory signals. J Immunol Baltim Md 1950. 2006;177(5):3242–3249. - PubMed